OPK OPKO HEALTH, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 944809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.3%
TTM net income YoY17.9%
TTM EPS YoY24.0%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-25.5%
Net margin-29.5%
FCF margin-27.0%
EBITDA margin-8.3%
Returns
ROE-12.2%
ROA-7.6%
ROIC (approx.)-12.4%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets40.6%
Debt / equity0.00x
Current ratio4.97x
Interest coverage2.08x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $606.88M | $713.14M |
| Cost of revenue | $400.94M | $494.63M |
| Gross profit | $205.94M | $218.51M |
| R&D expense | $124.03M | $105.21M |
| SG&A expense | $223.00M | $304.22M |
| Operating income | -$117.41M | -$152.06M |
| Interest expense | $0 | $47.47M |
| Pretax income | -$241.36M | -$10.36M |
| Income tax | -$15.71M | $42.84M |
| Net income | -$225.68M | -$53.22M |
| EBITDA | -$25.78M | -$53.89M |
| EPS (basic) | -0.30 | -0.08 |
| EPS (diluted) | -0.30 | -0.08 |
| Weighted avg. shares (diluted) | 751.13M | 694.02M |
| Balance sheet | ||
| Cash & equivalents | $364.41M | $426.58M |
| Receivables | $90.25M | $118.02M |
| Inventory | $52.73M | $56.80M |
| Current assets | $581.88M | $662.09M |
| PP&E, net | $72.81M | $70.13M |
| Goodwill | $320.85M | $529.25M |
| Intangibles | $446.43M | $616.61M |
| Total assets | $1.93B | $2.20B |
| Current liabilities | $146.68M | $193.10M |
| Short-term debt | $1.74M | $437.20M |
| Long-term debt | $2.26M | $3.00M |
| Total debt | $4.00M | $440.20M |
| Total liabilities | $663.98M | $834.76M |
| Shareholders' equity | $1.27B | $1.37B |
| Net debt | -$360.41M | $13.62M |
| Cash flow statement | ||
| Operating cash flow | -$178.54M | -$183.49M |
| Capital expenditure | $12.28M | $25.01M |
| Free cash flow | -$190.82M | -$208.50M |
| Investing cash flow | $230.30M | $352.21M |
| Financing cash flow | -$118.06M | $184.17M |
| Depreciation & amortization | $91.63M | $98.18M |
| Stock-based compensation | $10.71M | $11.05M |
| Share buybacks | $47.04M | $90.22M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.